Skip to content

Compliance

Compliance is inside the work, not after it.

Most agencies treat compliance as the client’s problem. The work is produced, submitted, rejected, revised, resubmitted. Each cycle costs a week, and the weeks are always taken from the end of the timeline — which is where the congress date sits.

In short

Hibridge operates an in-house pharmaceutical compliance team that reviews every deliverable before it is sent to the client. Review covers scientific claim substantiation against the approved label, promotional code positions for the relevant market, transfer-of-value treatment for HCP engagements, and personal data handling. The intent is that the client’s medical, legal and regulatory reviewers receive work with its predictable problems already removed.

What our review covers

01

Scientific claim substantiation

Every claim traced to the approved label or to a referenced, on-file source. Claims that cannot be substantiated are removed at the drafting stage rather than defended at review.

02

Promotional code positions

Assessment against the applicable code for the market in question — Egyptian requirements, GCC market codes, and global corporate policy where a multinational parent applies a stricter internal standard.

03

Transfer-of-value treatment

HCP engagement structured so that fair market value, contracting and spend capture are documented as the activity happens, not reconstructed afterwards for a disclosure deadline.

04

Data protection and consent

Personal data handling assessed against Egypt’s Personal Data Protection Law and, where an EU or UK parent is in scope, against GDPR. Consent architecture is decided before a system is configured.

05

Pharmacovigilance touchpoints

Any activity that can surface an adverse event — social channels, patient programmes, market research, congresses — gets a documented escalation route agreed with your PV function before launch.

06

Audit trail

Every deliverable arrives with its review record. If a regulator or an internal audit asks how a claim was approved, the answer exists as a document rather than a memory.

What we do not claim

We do not approve materials on your behalf, and we do not replace your MLR process. Regulatory accountability sits with the marketing authorisation holder and cannot be outsourced. What we remove is the avoidable rework — the predictable rejections that consume review cycles without adding safety.

The enforcement picture has changed

Promotional compliance in pharma spent several years in a low-enforcement environment. That has reversed sharply, and organisations that built habits during the quiet period are exposed.

~100

FDA warning letters to pharmaceutical companies fell to one in 2023 and zero in 2024. In September 2025 the agency issued approximately 100 cease-and-desist letters and thousands of warning letters in a single action.

U.S. Food and Drug Administration ·

38.4 weeks

A peer-reviewed analysis of 18 years of UK PMCPA records found 1,797 cases ruled involving 159 companies, with average time to rule rising from 11.8 weeks in 2004 to 38.4 weeks in 2021.

Regulation & Governance (peer-reviewed), reported by The Pharmaceutical Journal ·

Sources

Every figure on this page is attributed to its original publisher. Where a figure is organiser-reported or secondary, we say so.

  1. U.S. Food and Drug Administration — FDA Launches Crackdown on Deceptive Drug Advertising ·
  2. Regulation & Governance (peer-reviewed), reported by The Pharmaceutical Journal — Delayed rulings on drug company marketing code breaches "untenable" for patient health ·

These figures are from US and UK regulators. They matter regionally because multinational corporate policy is usually written to the strictest standard the group faces, and that standard is then applied to Egyptian and GCC affiliates.

Frequently asked questions

Does Hibridge approve materials on our behalf?
No. Regulatory accountability sits with the marketing authorisation holder and cannot be transferred to an agency. Hibridge pre-clears work internally so that the client’s MLR reviewers receive material with predictable problems already removed. Final approval remains yours.
What qualifies your compliance team?
The team is staffed by reviewers with in-house pharmaceutical experience — people who have sat on the client side of an MLR process rather than only submitted into one.
Which codes do you work against?
The applicable local code for the market, plus the client’s own corporate policy where it is stricter, which for multinational affiliates it usually is. We ask for your internal standard at kick-off rather than assuming the local minimum.
Does this slow delivery down?
It moves the review earlier, not later. Compliance positions are resolved during design, which is when changing them is cheap. The cost lands in week one instead of week nine.
Can you work with our existing MLR platform?
Yes. We prepare submissions in the format your platform and reviewers expect, including modular content structures where you use them.

Bring us the process that keeps slipping.

Usually it is a congress, a launch pack, or a social channel nobody wants to own.